Edition:
India

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

158.43USD
18 May 2018
Change (% chg)

$-1.80 (-1.12%)
Prev Close
$160.23
Open
$159.99
Day's High
$161.00
Day's Low
$158.01
Volume
634,843
Avg. Vol
777,163
52-wk High
$256.78
52-wk Low
$142.83

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

Financials

  AGN.N Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -11.66 -- --
ROI: -3.08 14.84 14.38
ROE: -5.61 16.34 16.07

Appaloosa gets permission for activist stance with Allergan stake

NEW YORK David Tepper's Appaloosa Management and two of his funds received Federal Trade Commission clearance earlier this week that could clear the way for the billionaire to become an activist investor in drugmaker Allergan Plc.

18 May 2018

Appaloosa gets permission for activist stance with Allergan stake

NEW YORK, May 17 David Tepper's Appaloosa Management and two of his funds received Federal Trade Commission clearance earlier this week that could clear the way for the billionaire to become an activist investor in drugmaker Allergan Plc.

18 May 2018

Evolus investors frown as FDA declines to approve Botox rival

U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines, sending its shares down as much as 35 percent.

16 May 2018

BRIEF-Evolus Appoints Allergan Aesthetics Head As President And Chief Executive Officer

* EVOLUS APPOINTS ALLERGAN AESTHETICS HEAD AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

07 May 2018

BRIEF-John Davidson Elected To Allergan Board Of Directors

* ALLERGAN PLC - ALLERGAN BOARD NOW HAS 12 MEMBERS Source text for Eikon: Further company coverage:

04 May 2018

BRIEF-Allergan Sets Quarterly Cash Dividend Of $0.72 Per Share

* SETS QUARTERLY CASH DIVIDEND OF $0.72PER SHARE Source text for Eikon: Further company coverage:

04 May 2018

BRIEF-Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent Litigation

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH AUROBINDO PHARMA RESOLVING LINZESS (LINACLOTIDE) PATENT LITIGATION

04 May 2018

Migraine drug delay would compound Teva's troubles

TEL AVIV Teva Pharmaceutical Industries is counting on its new migraine treatment to haul it out of the doldrums. But a possible delay in U.S. approval and looming pricing battle are making the task harder.

02 May 2018

US STOCKS-Wall St slides as healthcare drags but manages monthly gain

* Indexes dip: Dow 0.61 pct, S&P 0.82 pct, Nasdaq 0.75 pct (Updates to market close)

01 May 2018

US STOCKS-Wall St slides as healthcare drags, oil prices weigh

* Indexes dip: Dow 0.4 pct, S&P 0.6 pct, Nasdaq 0.6 pct (Updates to late afternoon, changes byline, adds NEW YORK to dateline)

01 May 2018

Earnings vs. Estimates